Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1966 2
1967 1
1968 2
1969 4
1970 1
1971 5
1972 3
1973 10
1974 9
1975 14
1976 7
1977 5
1978 7
1979 4
1980 6
1981 9
1982 1
1983 3
1984 1
1985 3
1986 8
1987 9
1988 5
1989 4
1990 5
1991 2
1992 1
1993 4
1994 1
1995 3
1996 4
1997 2
1998 2
1999 1
2000 2
2002 1
2004 1
2005 2
2007 2
2008 2
2009 1
2010 3
2011 4
2012 4
2013 2
2014 4
2015 7
2016 5
2017 3
2020 2
2021 1
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Among authors: stauch m. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. Langerbeins P, et al. Among authors: stauch m. Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845. Blood. 2022. PMID: 34758069 Free article. Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: stauch m. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: stauch m. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
Consent in medical law.
Stauch M. Stauch M. Br J Nurs. 1998 Jan 22-Feb 11;7(2):84. doi: 10.12968/bjon.1998.7.2.84. Br J Nurs. 1998. PMID: 9510682 Review. No abstract available.
Equilibrium (gated) radionuclide ventriculography.
Adam WE, Tarkowska A, Bitter F, Stauch M, Geffers H. Adam WE, et al. Among authors: stauch m. Cardiovasc Radiol. 1979 Sep;2(3):161-73. doi: 10.1007/BF02552061. Cardiovasc Radiol. 1979. PMID: 498193 No abstract available.
[Isotopic methods].
Stauch M, Kress G, Kress P, Adam WE. Stauch M, et al. Rev Esp Cardiol. 1985;38 Suppl 3:25-35. Rev Esp Cardiol. 1985. PMID: 4089292 Spanish. No abstract available.
[Alcoholic cardiomyopathy].
Sigel H, Nechwatal W, Graf R, Stauch M. Sigel H, et al. Among authors: stauch m. ZFA (Stuttgart). 1981 Jul 31;57(21):1462-8. ZFA (Stuttgart). 1981. PMID: 7281934 German. No abstract available.
[Antibodies instead of insulin?].
Anders S, Kühnemund L, Stauch M, Zündorf I, Dingermann T. Anders S, et al. Among authors: stauch m. Pharm Unserer Zeit. 2010 Mar;39(2):97-8. doi: 10.1002/pauz.201090017. Pharm Unserer Zeit. 2010. PMID: 20196056 German. No abstract available.
[Therapeutic electrostimulation].
Stauch M. Stauch M. Verh Dtsch Ges Inn Med. 1981;87:1387-93. Verh Dtsch Ges Inn Med. 1981. PMID: 6977244 German. No abstract available.
192 results